Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H12O7 |
Molecular Weight | 364.3051 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1=C(O)C2=C(C=C1)C3(OC(=O)C4=C3C=CC=C4)C5=C(O2)C(O)=C(O)C=C5
InChI
InChIKey=PHLYOKFVXIVOJC-UHFFFAOYSA-N
InChI=1S/C20H12O7/c21-13-7-5-11-17(15(13)23)26-18-12(6-8-14(22)16(18)24)20(11)10-4-2-1-3-9(10)19(25)27-20/h1-8,21-24H
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0031680 Sources: https://www.ncbi.nlm.nih.gov/pubmed/18006643 |
422.0 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Specificity in structure-based drug design: identification of a novel, selective inhibitor of Pneumocystis carinii dihydrofolate reductase. | 1997 Sep |
|
Inhibition of Gβγ-subunit signaling potentiates morphine-induced antinociception but not respiratory depression, constipation, locomotion, and reward. | 2013 Apr |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18006643
Oral administration of gallein (30 mg/kg) inhibited paw edema and neutrophil infiltration in a mouse carrageenan-induced paw edema model.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29084601
Gallein 10 uM was able to significantly counteract this β-ionone-induced LNCaP cell invasiveness.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
622478
Created by
admin on Sat Dec 16 08:03:01 GMT 2023 , Edited by admin on Sat Dec 16 08:03:01 GMT 2023
|
PRIMARY | |||
|
73685
Created by
admin on Sat Dec 16 08:03:01 GMT 2023 , Edited by admin on Sat Dec 16 08:03:01 GMT 2023
|
PRIMARY | |||
|
8L0084U2QR
Created by
admin on Sat Dec 16 08:03:01 GMT 2023 , Edited by admin on Sat Dec 16 08:03:01 GMT 2023
|
PRIMARY | |||
|
218-272-6
Created by
admin on Sat Dec 16 08:03:01 GMT 2023 , Edited by admin on Sat Dec 16 08:03:01 GMT 2023
|
PRIMARY | |||
|
DTXSID5062180
Created by
admin on Sat Dec 16 08:03:01 GMT 2023 , Edited by admin on Sat Dec 16 08:03:01 GMT 2023
|
PRIMARY | |||
|
2103-64-2
Created by
admin on Sat Dec 16 08:03:01 GMT 2023 , Edited by admin on Sat Dec 16 08:03:01 GMT 2023
|
PRIMARY | |||
|
8668
Created by
admin on Sat Dec 16 08:03:01 GMT 2023 , Edited by admin on Sat Dec 16 08:03:01 GMT 2023
|
PRIMARY | |||
|
88294
Created by
admin on Sat Dec 16 08:03:01 GMT 2023 , Edited by admin on Sat Dec 16 08:03:01 GMT 2023
|
PRIMARY | |||
|
m5644
Created by
admin on Sat Dec 16 08:03:01 GMT 2023 , Edited by admin on Sat Dec 16 08:03:01 GMT 2023
|
PRIMARY | Merck Index | ||
|
56445
Created by
admin on Sat Dec 16 08:03:01 GMT 2023 , Edited by admin on Sat Dec 16 08:03:01 GMT 2023
|
PRIMARY |
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD